72 related articles for article (PubMed ID: 24975746)
1. Expression of ProEx C in primary and metastatic urothelial carcinoma.
Liu L; Cohen C; Siddiqui MT
Diagn Cytopathol; 2015 Mar; 43(3):181-7. PubMed ID: 24975746
[TBL] [Abstract][Full Text] [Related]
2. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
3. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens.
Moatamed NA; Rao JY; Alexanian S; Cobarrubias M; Levin M; Lu D; Apple SK
Cancer Cytopathol; 2013 Jun; 121(6):320-8. PubMed ID: 23364848
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Yan S; Coffing BN; Li Z; Xie H; Brennick JB; Beg HA; Froehlich HM; Wells WA
Anticancer Res; 2016 Jun; 36(6):2871-80. PubMed ID: 27272799
[TBL] [Abstract][Full Text] [Related]
5. ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.
Botti G; Malzone MG; La Mantia E; Montanari M; Vanacore D; Rossetti S; Quagliariello V; Cavaliere C; Di Franco R; Castaldo L; Ametrano G; Cappuccio F; Romano FJ; Piscitelli R; Pepe MF; D'Aniello C; Facchini G
Int J Med Sci; 2017; 14(6):554-559. PubMed ID: 28638271
[TBL] [Abstract][Full Text] [Related]
6. GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases.
Siddiqui MT; Seydafkan S; Cohen C
Diagn Cytopathol; 2014 Sep; 42(9):809-15. PubMed ID: 24578300
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical patterns of ProEx C in vulvar squamous lesions: detection of overexpression of MCM2 and TOP2A.
Chen H; Gonzalez JL; Brennick JB; Liu M; Yan S
Am J Surg Pathol; 2010 Sep; 34(9):1250-7. PubMed ID: 20697251
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of ProEx C and ImmunoCyt/uCyt assays in atypical urine cytology.
Vergara-Lluri ME; Hu E; Rao JY; Levin M; Apple SK; Moatamed NA
Arch Pathol Lab Med; 2014 Sep; 138(9):1215-22. PubMed ID: 25171704
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study.
Halloush RA; Akpolat I; Jim Zhai Q; Schwartz MR; Mody DR
Cancer; 2008 Dec; 114(6):474-80. PubMed ID: 19016301
[TBL] [Abstract][Full Text] [Related]
10. Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx™ C assay: An immunoassay which detects aberrant S-phase induction in cervical tissue.
Dixon EP; King LM; Nelson R; Simkins SG; Knapp SL; Brough GH; Lenz KL; Henderson DT; Whitehead CM; Hessling J; Brown CA; Malinowski DP
J Immunol Methods; 2017 Mar; 442():35-41. PubMed ID: 28093271
[TBL] [Abstract][Full Text] [Related]
11. Fascin as an identifier of metastatic urothelial carcinoma: A retrospective study of fine-needle aspiration cell blocks and histologic tissue microarrays.
Vogt AP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2012 Oct; 40(10):882-6. PubMed ID: 21433004
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions.
Shi J; Liu H; Wilkerson M; Huang Y; Meschter S; Dupree W; Schuerch C; Lin F
Hum Pathol; 2007 Sep; 38(9):1335-44. PubMed ID: 17512033
[TBL] [Abstract][Full Text] [Related]
13. A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
Aximu D; Azad A; Ni R; Colgan T; Nanji S
Int J Gynecol Pathol; 2009 Mar; 28(2):114-9. PubMed ID: 19188825
[TBL] [Abstract][Full Text] [Related]
14. ProEx C stain analysis in recurrent respiratory papillomatosis.
Bhandarkar ND; Sims HS; David O
Ann Otol Rhinol Laryngol; 2010 Feb; 119(2):99-104. PubMed ID: 20336920
[TBL] [Abstract][Full Text] [Related]
15. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
16. Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens.
Oberg TN; Kipp BR; Vrana JA; Bartholet MK; Fales CJ; Garcia R; McDonald AN; Rosas BL; Henry MR; Clayton AC
Diagn Cytopathol; 2010 Aug; 38(8):564-72. PubMed ID: 19937941
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
[TBL] [Abstract][Full Text] [Related]
18. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
20. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
